Solriamfetol Hydrochloride

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H14N2O2.ClH
Molecular Weight	230.691
Optical Activity	( + )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.N[C@@H](COC(N)=O)CC1=CC=CC=C1

InChI

InChIKey=KAOVAAHCFNYXNJ-SBSPUUFOSA-N

InChI=1S/C10H14N2O2.ClH/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8;/h1-5,9H,6-7,11H2,(H2,12,13);1H/t9-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C10H14N2O2
Molecular Weight	194.2304
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800030225 | http://www.ajudaily.com/view/20190321120410966 | https://www.neurologylive.com/clinical-focus/solriamfetol-fda-approval-excessive-daytime-sleepiness-narcolepsy-obstructive-sleep-apnea | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf

ADX-N05, originally discovered by SK Holdings, is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). ADX-N05 (Solriamfetol, sold under the brand name Sunosi) is approved in the US and is under regulatory review in the EU to improve wakefulness in adult patients with hypersomnia associated with narcolepsy or obstructive sleep apnoea.The US FDA has approved solriamfetol (Sunosi, Jazz Pharmaceuticals) for the treatment of excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine transporter 183 Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29891587	Inhibitor 8504		2.9 µM [IC50]
Norepinephrine transporter 197 Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29891587	Inhibitor 8504		4.4 µM [IC50]

C_max

Value	Dose	Co-administered	Analyte	Population
499 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30865315/	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLRIAMFETOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
5273 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30865315/	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLRIAMFETOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
7.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30865315/	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLRIAMFETOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
112.5 mg 1 times / day steady, oral Recommended Dose: 112.5 mg, 1 times / day Route: oral Route: steady Dose: 112.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Other AEs: Decreased appetite, Insomnia... Other AEs: Decreased appetite (9%) Insomnia (5%) Anxiety (6%) Headache (16%) Palpitations (2%) Nausea (7%) Dry mouth (4%) Constipation (3%) Agitation (<2%) Bruxism (<2%) Irritability (<2%) Cough (<2%) Hyperhidrosis (<2%) Feeling jittery (<2%) Thirst (<2%) Chest discomfort (<2%) Chest pain (<2%) Weight decreased (<2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Disc. AE: Anxiety, Palpitations... Other AEs: Headache, Nausea... AEs leading to discontinuation/dose reduction: Anxiety (0.5%) Palpitations (0.5%) Restlessness (0.5%) Other AEs: Headache (13%) Nausea (9%) Decreased appetite (8%) Anxiety (7%) Dry mouth (4%) Diarrhea (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
37.5 mg 1 times / day steady, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: steady Dose: 37.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Other AEs: Headache, Nausea... Other AEs: Headache (7%) Nausea (7%) Decreased appetite (2%) Anxiety (2%) Dry mouth (2%) Diarrhea (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
75 mg 1 times / day steady, oral Recommended Dose: 75 mg, 1 times / day Route: oral Route: steady Dose: 75 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Other AEs: Headache, Nausea... Other AEs: Headache (9%) Nausea (5%) Decreased appetite (7%) Anxiety (3%) Dry mouth (3%) Diarrhea (4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
87.5 mg 1 times / day steady, oral Recommended Dose: 87.5 mg, 1 times / day Route: oral Route: steady Dose: 87.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Other AEs: Decreased appetite, Anxiety... Other AEs: Decreased appetite (6%) Anxiety (4%) Irritability (3%) Dizziness (2%) Palpitations (3%) Nausea (8%) Diarrhea (4%) Abdominal pain (3%) Dry mouth (3%) Feeling jittery (3%) Chest discomfort (2%) Hyperhidrosis (2%) Bruxism (<2%) Restlessness (<2%) Disturbance in attention (<2%) Tremor (<2%) Cough (<2%) Dyspnea (<2%) Constipation (<2%) Vomiting (<2%) Weight decreased (<2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
87.5 mg 1 times / day steady, oral Recommended Dose: 87.5 mg, 1 times / day Route: oral Route: steady Dose: 87.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	unhealthy, 18 to 75 years Health Status: unhealthy Age Group: 18 to 75 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Other AEs: Blood pressure systolic increased, Blood pressure diastolic increased... Other AEs: Blood pressure systolic increased Blood pressure diastolic increased Heart rate increased Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf
300 mg 1 times / day single, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: single Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30598342/	healthy, 19 to 54 years Health Status: healthy Age Group: 19 to 54 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/30598342/	Other AEs: Insomnia, Headache... Other AEs: Insomnia (grade 1, 21.9%) Headache (grade 1, 15.6%) Hypervigilance (grade 1, 9.4%) Decreased appetite (grade 1, 9.4%) Nausea (grade 1, 9.4%) Insomnia (grade 1, 21.9%) Headache (grade 1, 12.5%) Hypervigilance (grade 1, 12.5%) Decreased appetite (grade 1, 9.4%) Nausea (grade 1, 6.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/30598342/
1200 mg 1 times / day single, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: single Dose: 1200 mg, 1 times / day Sources: https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf https://pubmed.ncbi.nlm.nih.gov/30269642/	healthy, mean age 29.3 years Health Status: healthy Age Group: mean age 29.3 years Sex: M Sources: https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf https://pubmed.ncbi.nlm.nih.gov/30269642/	Disc. AE: Blood pressure increased, Nervousness... Other AEs: Hypervigilance, Elevated mood... AEs leading to discontinuation/dose reduction: Blood pressure increased (grade 1, 2.4%) Nervousness (grade 1, 2.4%) Other AEs: Hypervigilance (42.9%) Elevated mood (23.8%) Dry mouth (21.4%) Nausea (21.4%) Feeling of relaxation (19%) Decreased appetite (19%) Hyperhidrosis (19%) Insomnia (16.7%) Headache (14.3%) Restlessness (14.3%) Palpitations (11.9%) Paresthesia (7.1%) Sources: https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf https://pubmed.ncbi.nlm.nih.gov/30269642/
150 mg 1 times / day multiple, oral Studied dose Dose: 150 mg, 1 times / day Route: oral Route: multiple Dose: 150 mg, 1 times / day Sources: https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf	unhealthy Health Status: unhealthy Sex: M+F Sources: https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf	Disc. AE: Blood pressure increased, Hypertension... AEs leading to discontinuation/dose reduction: Blood pressure increased (0.48%) Hypertension (0.24%) Sources: https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 CYP2E1 1060 CYP3A4/5 296 UGT 45 P-gp 1741 BCRP 910 OATP1B1 1079 OATP1B3 961 OAT1 725 OAT3 747 OCT1 620 MATE2 267 OCTN1 32 OCTN2 71 OCT2 779 MATE1 415 UGT1A 4 UGT2B7 197	P-gp 2052 BCRP 697 OATP1B1 503 OATP1B3 435 OAT1 395 OAT3 391	CYP1A2 832 CYP2B6 669 CYP3A4/5 133 UGT 32

Drug as perpetrator

Target	Modality	Activity
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP3A4/5 357	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OCTN1 32	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OCTN2 71	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
UGT 70	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
UGT 70	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
UGT1A 6	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000PharmR.pdf#page=30 Page: 30.0	no
UGT2B7 210	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000PharmR.pdf#page=30 Page: 30.0	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	weak [IC50 146 uM]
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	weak [IC50 211 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000PharmR.pdf#page=30 Page: 30.0	weak [IC50 360 uM]

Drug as victim

Target	Modality	Activity
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000ClinPharmR.pdf#page=9 Page: 9.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000PharmR.pdf#page=20 Page: 20.0

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P01C3BA
A2B Chem	AW42982
AA Blocks	AA01C2RU
AChemBlock	Q69522
Chem Scene	CS-0031486	http://www.chemscene.com/178429-62-4.html
ChemShuttle	139041
Chemspace	CSSB00041015464	https://chem-space.com/CSSB00041015464
eMolecules	222563444
eMolecules	303230315
eMolecules	67911099
Enamine	BBV-44122269
Enamine	BBV-77772338
Enamine	EN300-253107
Hairui	R2CQ017
KeyOrganics	CS-2577
mcule	MCULE-3233675360
MedChem Express	HY-109043	https://www.medchemexpress.com/solriamfetol.html
Molnova	M12688
MolPort	MolPort-039-241-646
MolPort	MolPort-046-793-373
MolPort	MolPort-047-156-022
MuseChem	I009552
Smolecule	S543563	http://www.smolecule.com/products/s543563
Smolecule	S727641	https://www.smolecule.com/products/s727641
THE BioTek	bt-284158	https://www.thebiotek.com/product/inhibitors/bt-284158
THE BioTek	bt-386716	https://www.thebiotek.com/product/others/bt-386716
Toronto Research Chemicals	S676775
ZINC	ZINC000034278783	http://zinc15.docking.org/substances/ZINC000034278783

PubMed

Title	Date	PubMed
New developments in the management of narcolepsy.	2017	28424564
Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.	2016-07-01	27166238
Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.	2015-09	26298786

Sample Use Guides

In Vivo Use Guide

The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses.

Route of Administration: Oral

In Vitro Use Guide

Solriamfetol binds to the dopamine transporter and norepinephrine transporter with low affinity (Ki=14.2 uM and 3.7 uM, respectively), and inhibits the reuptake of dopamine and norepinephrine with low potency (IC50 =2.9 uM and 4.4 uM, respectively). Solriamfetol has no appreciable binding affinity for the serotonin transporter (Ki=81.5 uM) and does not inhibit serotonin reuptake (IC50 > 100 uM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:58:34 GMT 2025` Edited by `admin` on `Mon Mar 31 17:58:34 GMT 2025`
Record UNII	K7RO88SP7A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

JZP-110 HYDROCHLORIDE

Preferred Name

English

Solriamfetol Hydrochloride

Official Name

English

Solriamfetol hydrochloride [WHO-DD]

Common Name

English

ADX-N05 HYDROCHLORIDE

Code

English

ADX-N-05 HYDROCHLORIDE

Code

English

YKP-10A HYDROCHLORIDE

Code

English

SOLRIAMFETOL HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

(2R)-2-Amino-3-phenylpropyl carbamate, monohydrochloride

Systematic Name

English

BENZENEPROPANOL, .BETA.-AMINO-, 1-CARBAMATE, HYDROCHLORIDE (1:1), (.BETA.R)-

Systematic Name

English

SKL-N-05 HYDROCHLORIDE

Code

English

R-228060 HYDROCHLORIDE

Code

English

SOLRIAMFETOL HYDROCHLORIDE [USAN]

Common Name

English

SOLRIAMFETOL HYDROCHLORIDE [MI]

Common Name

English

(R)-(+)-2-AMINO-1-CARBAMOYLOXY-3-PHENYLPROPANE HYDROCHLORIDE

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

375112